Despite what the Immune Response BioPharma says about the Immune Response/Orchestra Thera research the last releases from the company certainly didn't sound good.
"CARLSBAD, Calif., July 17, Orchestra
Therapeutics, Inc. (OTC Bulletin Board: OCHT) announced today the
discontinuation of its HIV Vaccine Development Program. Analysis of data
from 70 patients who completed a 52 weeks clinical trial in Europe and
Canada did not show a clear advantage of Orchestra Therapeutics' second
generation HIV vaccine, IR103, over its original whole-killed HIV vaccine,
REMUNE(R). Furthermore, although interim analysis of patients in this trial
at 36 weeks suggested a trend toward stabilization of CD4+ counts in HAART
naive patients vaccinated with REMUNE(R) or IR103, this trend was not
observed at week 52."
No comments:
Post a Comment